Steven Kahn

Nov 18, 2024 | jacc.org | Subodh Verma |Scott Emerson |Jorge Plutzky |Steven Kahn

Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and ObesitySign in, Subscribe, or Pay to View

Sep 12, 2024 | healio.com | Michael Monostra |Erik Swain |Steven Kahn

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Greater weight loss at 1 year with tirzepatide improved the odds for sustaining an HbA1c of 6.5% or less at 2 years.

Jul 1, 2024 | digitalcommons.library.tmc.edu | Donna Ryan |Ildiko Lingvay |John Deanfield |Steven Kahn

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.